Cargando…
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053597/ https://www.ncbi.nlm.nih.gov/pubmed/33894473 http://dx.doi.org/10.1016/j.thromres.2021.04.008 |
| _version_ | 1783680153657802752 |
|---|---|
| author | Rhoades, Ruben Leong, Ron Kopenitz, Jason Thoma, Brandi McDermott, Lydia Dovidio, Joseph Barletti, Shannon Gong, Jerald Z. Massey, Howard T. McKenzie, Steven E. Rame, J. Eduardo Al-Rawas, Nawar |
| author_facet | Rhoades, Ruben Leong, Ron Kopenitz, Jason Thoma, Brandi McDermott, Lydia Dovidio, Joseph Barletti, Shannon Gong, Jerald Z. Massey, Howard T. McKenzie, Steven E. Rame, J. Eduardo Al-Rawas, Nawar |
| author_sort | Rhoades, Ruben |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8053597 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80535972021-04-19 Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy Rhoades, Ruben Leong, Ron Kopenitz, Jason Thoma, Brandi McDermott, Lydia Dovidio, Joseph Barletti, Shannon Gong, Jerald Z. Massey, Howard T. McKenzie, Steven E. Rame, J. Eduardo Al-Rawas, Nawar Thromb Res Letter to the Editors-in-Chief Elsevier Ltd. 2021-07 2021-04-19 /pmc/articles/PMC8053597/ /pubmed/33894473 http://dx.doi.org/10.1016/j.thromres.2021.04.008 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editors-in-Chief Rhoades, Ruben Leong, Ron Kopenitz, Jason Thoma, Brandi McDermott, Lydia Dovidio, Joseph Barletti, Shannon Gong, Jerald Z. Massey, Howard T. McKenzie, Steven E. Rame, J. Eduardo Al-Rawas, Nawar Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title | Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title_full | Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title_fullStr | Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title_full_unstemmed | Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title_short | Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy |
| title_sort | coagulopathy monitoring and anticoagulation management in covid-19 patients on ecmo: advantages of a heparin anti-xa-based titration strategy |
| topic | Letter to the Editors-in-Chief |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053597/ https://www.ncbi.nlm.nih.gov/pubmed/33894473 http://dx.doi.org/10.1016/j.thromres.2021.04.008 |
| work_keys_str_mv | AT rhoadesruben coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT leongron coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT kopenitzjason coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT thomabrandi coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT mcdermottlydia coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT dovidiojoseph coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT barlettishannon coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT gongjeraldz coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT masseyhowardt coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT mckenziestevene coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT ramejeduardo coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy AT alrawasnawar coagulopathymonitoringandanticoagulationmanagementincovid19patientsonecmoadvantagesofaheparinantixabasedtitrationstrategy |